☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
boehringer ingelheim
Boehringer Ingelheim Reports Additional Data from the P-II Study of Survodutide to Treat Metabolic Dysfunction-Associated Steatohe...
June 7, 2024
Boehringer Ingelheim and OSE Immunotherapeutics Expand Partnership to Develop Therapies for Cancer and Cardio-Renal-Metabolic (CRM...
May 22, 2024
Boehringer Ingelheim Partners with Quallent Pharmaceuticals to Expand the Access of Cyltezo (Biosimilar, Humira)
May 15, 2024
Boehringer Ingelheim Introduces Bultavo 3 Vaccine Against Bluetongue Virus Serotype 3 for Sheep and Cattle
May 14, 2024
Boehringer Ingelheim Collaborates with Walgreens to Improve Clinical Trials Access
May 3, 2024
The US FDA Approves High Concentration of Boehringer Ingelheim's Cyltezo (Biosimilar, Humira)
May 2, 2024
Load more...
Back to Home